Who is eligible for clinical trial NCT04323189?

Participants must meet protocol criteria for Genetics Disease. Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT04323189 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-01-15

Effects of Sitagliptin in Individuals With Genetically Decreased DPP4 (NCT04323189)

🔵 Active, Not Recruiting Phase4 💊 Investigational Drug / Biologic Sponsor: University of Pennsylvania

🩺 Plain-English Summary (8th-Grade Level)

This is a pilot clinical trial to test the hypothesis that during sitagliptin (DPP4 inhibitor), individuals heterozygous for DPP4 loss of function variants will have a reduction in DPP4 activity and antigen, lower glucose after a mixed meal, and higher levels of intact DPP4 substrates compared to during placebo and compared to matched controls.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (3 items) and avoid the listed exclusions (18 items).

Location: University of Pennsylvania — Philadelphia, Pennsylvania

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Participant of the Penn Medicine Biobank who is willing to be recontacted to participate in future research.
Cases are defined as adults 18-70 years with likely decreased DPP4.
Controls are defined as adults who are matched to cases by: age, gender, race, BMI, hypertension status, diabetes status, renal function, and medication use that may affect outcomes of interest.

Usually NOT eligible if any of the following apply:

Exclusion Criteria:
The study will exclude volunteers with any significant medical conditions that may interfere with study participation, data interpretation, or pose safety risk(s) to the subject.
Recent hospitalization or acute illness such as infection within the past two weeks
Pregnancy
Use of insulin
Use of a GLP-1 agonist or DPP4 inhibitor medication
Use of oral diabetes agents other than metformin unless matched with controls
Type 1 diabetes
Chronic steroid use or use within the last 30 days
Significant liver disease including liver enzymes \>3 x upper limit of normal range
Renal dysfunction defined as eGFR\< 50mL/min/1.73m2
Significant cardiac disease such as heart transplantation

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (1 Sites)

University of Pennsylvania — Philadelphia, Pennsylvania

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

🏛️ View Official NIH Record ↗